Clinical Trials Browser

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

NCT02311959 2026-04-14

MAPAM-01

Phase 3 Completed

450 enrolled

Breast

Breast Neoplasms, Carcinoma in Situ

NCT06833073 2026-04-06

INTerpath-011

Phase 2 Recruiting

308 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT06056843 2026-04-03

PUD

Phase NA Completed

150 enrolled

Breast

Breast Neoplasms, Carcinoma in Situ

NCT06876038 2026-03-19

Low-cost Screening and Image-guided Photodynamic Therapy (PDT) of Premalignant and Malignant Oral Lesions

Phase 2 Not yet recruiting

65 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma in Situ, Leukoplakia, Oral, Mouth Neoplasms, Lichen Planus, Oral

NCT07480356 2026-03-18

ADVANCED-3

Phase 3 Not yet recruiting

284 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Neoplasms

NCT03258593 2026-03-17

Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)

Phase 1 Completed

15 enrolled 21 charts

Genitourinary

Urinary Bladder Neoplasms, Carcinoma in Situ

NCT04452591 2026-03-16

BOND-003

Phase 3 Active not recruiting

190 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ

NCT02858310 2026-03-09

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

Phase 1/2 Completed

224 enrolled 15 charts

Gynecologic

Carcinoma in Situ, Uterine Cervical Dysplasia, Vulvar Diseases, Vulvar Neoplasms, Papillomavirus Infections

NCT06115486 2026-02-04

EXERT-BCH Exercise Regimen to Improve Muscle Mass After Treatment of Breast Cancer

Phase NA Recruiting

30 enrolled

Breast

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma in Situ, Hypertrophy, Motor Activity, Neoplasms

NCT05951179 2026-01-27

ADVANCED-2

Phase 2 Recruiting

131 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT04752722 2026-01-26

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

Phase 1/2 Recruiting

350 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT07283835 2026-01-21

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Phase 2 Recruiting

16 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ

Clinical Trials

Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC

MAPAM-01

INTerpath-011

PUD

Low-cost Screening and Image-guided Photodynamic Therapy (PDT) of Premalignant and Malignant Oral Lesions

ADVANCED-3

Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)

BOND-003

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

EXERT-BCH Exercise Regimen to Improve Muscle Mass After Treatment of Breast Cancer

ADVANCED-2

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin